Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.

Saved in:
Bibliographic Details
Title: Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Authors: Colca JR; Metabolic Solutions Development Company, Kalamazoo, Michigan, USA. jcolca@msdrx.com, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, Zhou R, Orloff DG
Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2013 Apr; Vol. 93 (4), pp. 352-9. Date of Electronic Publication: 2013 Jan 18.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-6535
DOI:10.1038/clpt.2013.10